drugset / Trial / NCT05436639
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
NaSingle-groupOpen-labelTreatment
Summary
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2024-12-01
- Completion
- 2025-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | clofutriben | Small molecule | 2 mg | Oral |